Close Menu

NEW YORK (GenomeWeb) – PreludeDx said today that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved its DCISionRT test, which assesses recurrence risk and can predict radiation therapy benefit in patients diagnosed with non-invasive breast cancers known as ductal carcinoma in situ (DCIS).

PreludeDx's laboratory is also accredited by the College of American Pathology and has CLIA certification, so with CLEP approval, DCISionRT is now available in all 50 US states, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.